Back to Browse Journals » Clinical Epidemiology » Volume 5 » Issue 1

The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)

Authors Höybye C, Sävendahl L, Christesen HT, Lee P, Pedersen BT, Schlumpf M, Germak J, Ross J

Published Date April 2013 Volume 2013:5(1) Pages 119—127

DOI http://dx.doi.org/10.2147/CLEP.S42602

Received 10 January 2013, Accepted 13 February 2013, Published 26 April 2013

Charlotte Höybye,1 Lars Sävendahl,2 Henrik Thybo Christesen,3 Peter Lee,4 Birgitte Tønnes Pedersen,5 Michael Schlumpf,6 John Germak,7 Judith Ross8

1Department of Molecular Medicine and Surgery, Karolinska Institute and Department of Endocrinology, Metabolism and Diabetes, 2Department of Women’s and Children’s Health, Karolinska Institute and Division of Pediatrics, Karolinska University Hospital, Stockholm, Sweden; 3Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark; 4Department of Pediatrics, Penn State College of Medicine, Hershey, PA, USA; 5Global Development, Novo Nordisk A/S, Søborg, Denmark; 6Global Medical Affairs Biopharm, Novo Nordisk Health Care AG, Zurich, Switzerland; 7Clinical Development and Medical Affairs, Novo Nordisk Inc, Princeton, NJ, USA; 8Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA

Objective: Randomized controlled trials have shown that growth hormone (GH) therapy has effects on growth, metabolism, and body composition. GH therapy is prescribed for children with growth failure and adults with GH deficiency. Carefully conducted observational study of GH treatment affords the opportunity to assess long-term treatment outcomes and the clinical factors and variables affecting those outcomes, in patients receiving GH therapy in routine clinical practice.
Design: The NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web Enabled Research (ANSWER Program®) are two complementary, non-interventional, observational studies that adhere to current guidelines for pharmacoepidemiological data.
Patients: The studies include pediatric and adult patients receiving Norditropin®, as prescribed by their physicians.
Measurements: The studies gather long-term data on the safety and effectiveness of real-life treatment with the recombinant human GH, Norditropin®. We describe the origins, aims, objectives, and design methodology of the studies, as well as their governance and validity, strengths, and limitations.
Conclusion: The NordiNet® IOS and ANSWER Program® studies will provide valid insights into the effectiveness and safety of GH treatment across a diverse and large patient population treated in accordance with real-world clinical practice and following the Good Pharmacoepidemiological Practice and STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines.

Keywords: growth hormone replacement therapy, treatment outcome, pharmacoepidemiology, survey

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Socioeconomic status in HCV infected patients – risk and prognosis

Omland LH, Osler M, Jepsen P, Krarup H, Weis N, Christensen PB, Roed C, Sørensen HT, Obel N

Clinical Epidemiology 2013, 5:163-172

Published Date: 31 May 2013

Epidemiology and therapies for metastatic sarcoma

Amankwah EK, Conley AP, Reed DR

Clinical Epidemiology 2013, 5:147-162

Published Date: 16 May 2013

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction

Gacci M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, McVary KT, Kaplan SA, Maggi M, Carini M, Oelke M

Research and Reports in Urology 2013, 5:99-111

Published Date: 26 April 2013

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:171-185

Published Date: 26 April 2013

Registration of acute medical hospital admissions in the Danish National Patient Registry: a validation study

Vest-Hansen B, Riis AH, Christiansen CF

Clinical Epidemiology 2013, 5:129-133

Published Date: 26 April 2013

Heart disease as a risk factor for dementia

Ng JB, Turek M, Hakim AM

Clinical Epidemiology 2013, 5:135-145

Published Date: 26 April 2013

Assessment of the quality of existing patient educational tools focused on sudden cardiac arrest: a systematic evaluation by the Sudden Cardiac Arrest Thought Leadership Alliance

Hazelton G, Al-Khatib SM, Fonarow GC, Thomas KL, Hayes D, Sanders GD, Campbell SM, Yancy C, Peterson ED, Sears S

Patient Preference and Adherence 2013, 7:361-368

Published Date: 26 April 2013

Association of physical inactivity with circulatory disease events and hospital treatment costs

Davey RC, Cochrane T

Clinical Epidemiology 2013, 5:111-118

Published Date: 17 April 2013

Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions

Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT

Clinical Epidemiology 2012, 4:303-313

Published Date: 12 November 2012